Abstract

Objectives: The objective of this lecture is to review the role of botulinum toxin type A in the prevention and management of chronic migraine, with a focus on mechanism of action, patient selection, injection protocols, and long-term clinical outcomes. The session aims to provide practical guidance for clinicians integrating botulinum toxin into multidisciplinary migraine care while optimizing safety, efficacy, and patient satisfaction. Introduction: Botulinum toxin has evolved from an aesthetic and neuromuscular treatment into a cornerstone therapy for chronic migraine prevention. Dr. Patrick Treacy was among the earliest clinicians to recognize its therapeutic potential, first using botulinum toxin for migraine management in 2001, well before large-scale randomized trials and regulatory approval. Early clinical observations demonstrated reductions in headache frequency and intensity, supporting further investigation into its neuromodulatory effects on nociceptive pathways and contributing to the development of standardized treatment Materials / method: This lecture reviews published clinical evidence, including pivotal randomized controlled trials and real-world outcome data, alongside extensive clinical experience in migraine management using botulinum toxin type A. Injection techniques are based on the PREEMPT protocol, with discussion of anatomical landmarks, dosing strategies, fixed-site and follow-the-pain approaches, and adaptations for individual patient anatomy and symptom patterns. Patient selection criteria, treatment intervals, and assessment tools for measuring therapeutic response are also examined. Results: Clinical evidence and long-term real-world experience demonstrate that botulinum toxin type A significantly reduces migraine frequency, headache days, and migraine-related disability in patients with chronic migraine. Improvements are often sustained with repeated treatment cycles, with a favorable safety and tolerability profile. Optimal outcomes are associated with accurate diagnosis, appropriate patient selection, adherence to standardized injection protocols, and individualized treatment adjustments. Botulinum toxin also shows benefit used in combination with other preventive strategies Conclusion: Botulinum toxin type A represents a safe, effective, and well-established preventive treatment for chronic migraine when applied using appropriate patient selection and standardized injection techniques. Long-term clinical experience and robust trial data confirm sustained reductions in migraine frequency and disability. Ongoing refinement of protocols and combination with emerging therapies continue to enhance outcomes, reinforcing botulinum toxin as a central component of comprehensive, multidisciplinary migraine management.